Anavex Life Sciences Corp (AVXL)

[XenaLives]

N.A. sites will have to be added under the ACTC because U.S. medical system's manner of diagnosing and treating Alzheimer's is too random.

Chairman of the NIH/ACTC is Dr Paul Aisen MD he joined Anavex SAB in 2011 and is still a member.
Now what are the chances that A2-73 will be included in the ACTC?
What are the chances that this is why no N American sites for the latest A2-73 trial have been announced yet?
For those preoccupied with current share price of AVXL, how big a catalyst will it be for the stock if A2-73 is included in the ACTC in just a few short months?

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147095754

I expect it will be a P4 after several other countries have approved 2-73. The FDA will have too much political pressure on it so it will approve too. This could be another reason why Biogen just abandoned an ACTC funded trial, the ACTC knew it was wasting funds.